Myriad Genetics (MYGN) Set to Announce Earnings on Thursday

Myriad Genetics (NASDAQ:MYGNGet Rating) is scheduled to be releasing its earnings data before the market opens on Thursday, May 5th. Analysts expect Myriad Genetics to post earnings of ($0.15) per share for the quarter. Myriad Genetics has set its FY22 guidance at $0.00-$0.20 EPS and its FY 2022 guidance at $0.000-$0.200 EPS.

Myriad Genetics (NASDAQ:MYGNGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.04. Myriad Genetics had a negative net margin of 3.94% and a negative return on equity of 2.93%. The firm had revenue of $160.80 million for the quarter, compared to the consensus estimate of $162.21 million. During the same period in the prior year, the firm posted ($0.19) EPS. The firm’s revenue was up 4.0% compared to the same quarter last year. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ MYGN opened at $21.35 on Friday. Myriad Genetics has a 12 month low of $20.61 and a 12 month high of $36.95. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -56.18 and a beta of 1.53. The company’s fifty day moving average price is $24.31 and its two-hundred day moving average price is $26.54.

In other news, insider Jayne B. Hart sold 10,500 shares of the firm’s stock in a transaction dated Monday, February 28th. The shares were sold at an average price of $25.00, for a total value of $262,500.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 1.70% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Vident Investment Advisory LLC acquired a new stake in shares of Myriad Genetics in the 4th quarter worth about $204,000. Janus Henderson Group PLC acquired a new stake in shares of Myriad Genetics in the 3rd quarter worth about $245,000. Royal Bank of Canada increased its holdings in shares of Myriad Genetics by 55.5% in the 3rd quarter. Royal Bank of Canada now owns 10,870 shares of the company’s stock worth $352,000 after acquiring an additional 3,879 shares during the period. Allstate Corp increased its holdings in shares of Myriad Genetics by 49.7% in the 4th quarter. Allstate Corp now owns 16,416 shares of the company’s stock worth $453,000 after acquiring an additional 5,451 shares during the period. Finally, State of Tennessee Treasury Department increased its holdings in shares of Myriad Genetics by 1.0% in the 4th quarter. State of Tennessee Treasury Department now owns 43,771 shares of the company’s stock worth $1,208,000 after acquiring an additional 417 shares during the period. Institutional investors own 98.54% of the company’s stock.

MYGN has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 20th. The Goldman Sachs Group reduced their price objective on shares of Myriad Genetics from $26.00 to $23.00 and set a “sell” rating on the stock in a research note on Tuesday, April 19th.

About Myriad Genetics (Get Rating)

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Recommended Stories

Earnings History for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.